Literature DB >> 11888682

Locating the active site for angiogenesis and cell proliferation due to fibrin fragment E with a phage epitope display library.

C M Stirk1, A Reid, W T Melvin, W D Thompson.   

Abstract

The plasmin-mediated lysis of fibrin present in a wound, or in chronic inflammatory disease, results in the release of fibrin degradation products. One of the two major products is fibrin fragment E, which has been shown to stimulate cell proliferation in many cell types including endothelium, fibroblasts, and smooth muscle cells, and to be angiogenic in the chick chorioallantoic membrane (CAM) system. The activity of fibrin fragment E is dependent on N-terminus thrombin action. Antibodies against fibrin E, which block the cell proliferative activity, were used to locate the active site. Phage epitope display libraries were used to identify the sequence of a peptide, which resembles a region of the N terminus structure. The equivalent synthetic peptide (WTM110) has optimal stimulatory properties at equimolar concentrations to the parent molecule. Such peptide information has therapeutic potential for both stimulating and suppressing angiogenesis and cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11888682     DOI: 10.1016/s0306-3623(01)00114-8

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  3 in total

1.  Fibrinogen inhibits fibroblast-mediated contraction of collagen.

Authors:  Yih-Dar Nien; Yuan-Ping Han; Bill Tawil; Linda S Chan; Tai-Lan Tuan; Warren L Garner
Journal:  Wound Repair Regen       Date:  2003 Sep-Oct       Impact factor: 3.617

2.  Apolipoprotein(a) inhibits in vitro tube formation in endothelial cells: identification of roles for Kringle V and the plasminogen activation system.

Authors:  Lei Liu; Michael B Boffa; Marlys L Koschinsky
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

3.  Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer.

Authors:  R Salgado; I Benoy; R Weytjens; D Van Bockstaele; E Van Marck; Ph Huget; M Hoylaerts; P Vermeulen; L Y Dirix
Journal:  Br J Cancer       Date:  2002-12-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.